|
Synonyms: Dipeptide 9f [PMID 19175320] | GAP-486 | ZP-123
Compound class:
Peptide
Comment: Rotigaptide (GAP-486, and formerly ZP-123) is a hexapeptide developed originally by Wyeth, as an anti-arrhythmic agent. It promotes electrical coupling between ventricular myocytes by increasing gap junction conductance, via modulation of connexin 43< Reference id=31073/>. A recent study showed reduction in myocardial infarction size in a porcine model and protection from IRI-related endothelial dysfunction in man. Rotigaptide may thus have therapeutic potential in the treatment of myocardial infarction [1].
|
|
|||||||||||||||||
| No information available. |
Summary of Clinical Use ![]() |
| Rotigaptide was progressed as a clinical candidate, but phase 2 studies were terminated when the developers moved their focus to the orally active successor compound danegaptide (ZP1609, GAP-134). |